Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers

Research output: Contribution to journalArticle

Abstract

Oral delivery is the most common method for drug administration. However, poor solubility, stability, and bioavailability of many drugs make achieving therapeutic levels via the gastrointestinal (GI) tract challenging. Drug delivery must overcome numerous hurdles, including the acidic gastric environment and the continuous secretion of mucus that protects the GI tract. Nanoparticle drug carriers that can shield drugs from degradation and deliver them to intended sites within the GI tract may enable more efficient and sustained drug delivery. However, the rapid secretion and shedding of GI tract mucus can significantly limit the effectiveness of nanoparticle drug delivery systems. Many types of nanoparticles are efficiently trapped in and rapidly removed by mucus, making controlled release in the GI tract difficult. This review addresses the protective barrier properties of mucus secretions, how mucus affects the fate of orally administered nanoparticles, and recent developments in nanoparticles engineered to penetrate the mucus barrier.

Original languageEnglish (US)
Pages (from-to)557-570
Number of pages14
JournalAdvanced Drug Delivery Reviews
Volume64
Issue number6
DOIs
StatePublished - May 1 2012

Fingerprint

Mucus
Nanoparticles
Gastrointestinal Tract
Pharmaceutical Preparations
Drug Carriers
Drug Delivery Systems
Solubility
Biological Availability
Stomach

Keywords

  • Mucoadhesion
  • Mucus barrier
  • Mucus penetrating particles
  • Oral delivery

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Oral drug delivery with polymeric nanoparticles : The gastrointestinal mucus barriers. / Ensign-Hodges, Laura; Cone, Richard; Hanes, Justin S.

In: Advanced Drug Delivery Reviews, Vol. 64, No. 6, 01.05.2012, p. 557-570.

Research output: Contribution to journalArticle

@article{20b8162a661e4ced8a119d3eacdf0c35,
title = "Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers",
abstract = "Oral delivery is the most common method for drug administration. However, poor solubility, stability, and bioavailability of many drugs make achieving therapeutic levels via the gastrointestinal (GI) tract challenging. Drug delivery must overcome numerous hurdles, including the acidic gastric environment and the continuous secretion of mucus that protects the GI tract. Nanoparticle drug carriers that can shield drugs from degradation and deliver them to intended sites within the GI tract may enable more efficient and sustained drug delivery. However, the rapid secretion and shedding of GI tract mucus can significantly limit the effectiveness of nanoparticle drug delivery systems. Many types of nanoparticles are efficiently trapped in and rapidly removed by mucus, making controlled release in the GI tract difficult. This review addresses the protective barrier properties of mucus secretions, how mucus affects the fate of orally administered nanoparticles, and recent developments in nanoparticles engineered to penetrate the mucus barrier.",
keywords = "Mucoadhesion, Mucus barrier, Mucus penetrating particles, Oral delivery",
author = "Laura Ensign-Hodges and Richard Cone and Hanes, {Justin S}",
year = "2012",
month = "5",
day = "1",
doi = "10.1016/j.addr.2011.12.009",
language = "English (US)",
volume = "64",
pages = "557--570",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Oral drug delivery with polymeric nanoparticles

T2 - The gastrointestinal mucus barriers

AU - Ensign-Hodges, Laura

AU - Cone, Richard

AU - Hanes, Justin S

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Oral delivery is the most common method for drug administration. However, poor solubility, stability, and bioavailability of many drugs make achieving therapeutic levels via the gastrointestinal (GI) tract challenging. Drug delivery must overcome numerous hurdles, including the acidic gastric environment and the continuous secretion of mucus that protects the GI tract. Nanoparticle drug carriers that can shield drugs from degradation and deliver them to intended sites within the GI tract may enable more efficient and sustained drug delivery. However, the rapid secretion and shedding of GI tract mucus can significantly limit the effectiveness of nanoparticle drug delivery systems. Many types of nanoparticles are efficiently trapped in and rapidly removed by mucus, making controlled release in the GI tract difficult. This review addresses the protective barrier properties of mucus secretions, how mucus affects the fate of orally administered nanoparticles, and recent developments in nanoparticles engineered to penetrate the mucus barrier.

AB - Oral delivery is the most common method for drug administration. However, poor solubility, stability, and bioavailability of many drugs make achieving therapeutic levels via the gastrointestinal (GI) tract challenging. Drug delivery must overcome numerous hurdles, including the acidic gastric environment and the continuous secretion of mucus that protects the GI tract. Nanoparticle drug carriers that can shield drugs from degradation and deliver them to intended sites within the GI tract may enable more efficient and sustained drug delivery. However, the rapid secretion and shedding of GI tract mucus can significantly limit the effectiveness of nanoparticle drug delivery systems. Many types of nanoparticles are efficiently trapped in and rapidly removed by mucus, making controlled release in the GI tract difficult. This review addresses the protective barrier properties of mucus secretions, how mucus affects the fate of orally administered nanoparticles, and recent developments in nanoparticles engineered to penetrate the mucus barrier.

KW - Mucoadhesion

KW - Mucus barrier

KW - Mucus penetrating particles

KW - Oral delivery

UR - http://www.scopus.com/inward/record.url?scp=84859719708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859719708&partnerID=8YFLogxK

U2 - 10.1016/j.addr.2011.12.009

DO - 10.1016/j.addr.2011.12.009

M3 - Article

C2 - 22212900

AN - SCOPUS:84859719708

VL - 64

SP - 557

EP - 570

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

IS - 6

ER -